Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Up 5.8% in September

Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 349,600 shares, a growth of 5.8% from the September 15th total of 330,300 shares. Approximately 9.8% of the company’s stock are short sold. Based on an average trading volume of 144,200 shares, the days-to-cover ratio is currently 2.4 days.

Wall Street Analyst Weigh In

Separately, Maxim Group began coverage on shares of Aytu BioPharma in a research report on Wednesday, August 9th. They set a “buy” rating and a $5.00 price target for the company.

Get Aytu BioPharma alerts:

Read Our Latest Research Report on AYTU

Aytu BioPharma Stock Performance

Shares of AYTU opened at $3.14 on Wednesday. Aytu BioPharma has a 12 month low of $1.38 and a 12 month high of $4.88. The stock has a fifty day moving average price of $2.04 and a 200-day moving average price of $1.95. The company has a current ratio of 0.92, a quick ratio of 0.76 and a debt-to-equity ratio of 0.28. The firm has a market cap of $11.87 million, a PE ratio of -0.53 and a beta of -0.57.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors have recently added to or reduced their stakes in the business. Prudential Financial Inc. acquired a new position in shares of Aytu BioPharma in the 2nd quarter valued at $28,000. Commonwealth Equity Services LLC raised its stake in shares of Aytu BioPharma by 91.0% in the third quarter. Commonwealth Equity Services LLC now owns 209,558 shares of the company’s stock worth $38,000 after purchasing an additional 99,859 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Aytu BioPharma by 15.5% during the second quarter. Renaissance Technologies LLC now owns 57,323 shares of the company’s stock worth $92,000 after purchasing an additional 7,700 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Aytu BioPharma in the first quarter valued at approximately $106,000. Finally, Millennium Management LLC increased its holdings in Aytu BioPharma by 190.3% in the 4th quarter. Millennium Management LLC now owns 1,189,958 shares of the company’s stock worth $225,000 after buying an additional 780,116 shares during the period. Institutional investors and hedge funds own 45.09% of the company’s stock.

About Aytu BioPharma

(Get Free Report)

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers.

Read More

• Five stocks we like better than Aytu BioPharma
• Best Stocks Under $5.00
• Analysts Recommend These Stocks To Cushion The Automotive Slump
• 3 Home Improvement Stocks that Can Upgrade Your Portfolio
• Hyatt Hotels Earning Analysts Love, Buy The Dip?
• Why Special Dividends Can be a Delightful Surprise for Income Investors
• Business is Good for Lockheed Martin; Shares are Ready to Soar.

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.